Election Day will determine which party controls Congress for the next two years. But party control alone won't tell us where health policy is headed.
Across both parties, affordability concerns and growing skepticism of large institutions are reshaping policy debates, creating unexpected areas of convergence alongside familiar partisan divides. Regardless of the outcome, the 120th Congress will also bring new members, committee dynamics, policy priorities and oversight agendas.
For health care organizations, the weeks surrounding Election Day should be less about predicting the outcome and more about preparing for what comes next.
Control of Congress matters, but it’s not the only thing
A Democratic majority in either chamber could significantly change the health policy landscape. New committee leaders would set different legislative and oversight agendas and gain leverage in negotiations over must-pass legislation.
Continued Republican control would provide greater continuity, but new members and evolving Trump administration priorities would still change the environment.
Beyond the topline results, organizations should watch who will lead key committees, which incoming members bring health care experience or interest, and where influence within each party may be shifting.
If Democrats gain power, consider the agenda already taking shape
Democratic policy activity in 2026 offers clues about where congressional attention could turn.
- Drug pricing and affordability would likely remain central. Democrats could pursue efforts to build on the Inflation Reduction Act's Medicare drug negotiation provisions, address manufacturer pricing and patient out-of-pocket costs, and scrutinize the administration's Most Favored Nation (MFN) drug pricing initiatives.
- Coverage and access could return to the forefront, with renewed attention to Affordable Care Act (ACA) affordability, Medicaid coverage and public coverage alternatives.
- Health system accountability may result in broader coalitions. Pharmacy benefit managers (PBMs), insurer practices, provider consolidation, private equity, 340B and questions about where health care dollars flow have attracted interest across the political spectrum.
Watch for convergence, not just conflict
Some of the next Congress's most consequential health policy debates may not follow traditional partisan lines.
Recent polling suggests voters across the political spectrum are receptive to government intervention framed around affordability and fairness. That could reinforce momentum around drug affordability, PBM and insurer scrutiny, hospital costs, price transparency and policies giving consumers greater visibility into health care spending.
Republicans and Democrats may favor different solutions to these challenges. But concerns about cost, access, transparency and institutional accountability increasingly cross partisan lines, potentially creating unexpected coalitions.
That means reconsidering whether messages built around traditional partisan priorities will resonate with a changing political audience.
Oversight could matter as much as legislation
Election scenarios are often evaluated by asking: What legislation could pass? But that misses the broader context.
If Democrats gain control of at least one chamber, congressional oversight could become an immediate priority. Existing concerns could translate into hearings and investigations involving HHS and federal health agencies, Medicaid and coverage policy, vaccines and public health, and the administration's MFN initiatives and TrumpRx.
Even organizations not directly targeted could become part of broader debates through information requests, hearings, media attention or scrutiny of industry practices.
The question isn't only “What could Congress legislate?” but also “What could Congress investigate, and where might our organization or industry intersect with that scrutiny?”
Regardless of who wins, the audience is changing
New members, staff and committee assignments will create opportunities for organizations to educate policymakers on complex health policy issues. Materials developed for experienced audiences may not resonate with a freshman member or staffer encountering IRA implementation, 340B or reimbursement policy for the first time.
That changing audience extends beyond the Beltway. State elections will also bring changes in governors' offices, legislatures and committee leadership that could reshape debates over drug affordability, coverage, 340B and rural health priorities.
As affordability and accountability gain prominence across party lines, organizations must also be prepared to explain how their organizations and their policy positions deliver tangible value for patients and the health care system.
Now is the time to ask: Is our corporate narrative ready for 2027? Can new policymakers quickly understand our role and priorities? Are our messages relevant across different political environments?
Don’t wait until after November 3 to prepare
Organizations don't need election results to begin preparing. Many of the most valuable steps are “no-regret” actions that will remain relevant regardless of the outcome.
The weeks ahead offer an opportunity to refresh corporate narratives and policy messages, assess materials for new policymakers, and develop scenario-based stakeholder maps. Organizations can also identify potential legislative and oversight exposure, pressure-test positions against questions from both parties, and strengthen their arguments with additional evidence, patient perspectives or credible third-party voices.
The goal isn't to develop a separate strategy for every possible outcome but rather to understand what could change, who will need to be engaged and how to communicate value in the new environment.
.png)
